% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Talbot:144449,
      author       = {C. J. Talbot and M. R. Veldwijk and D. Azria and C. Batini
                      and M. Bierbaum and M. Brengues and J. Chang-Claude$^*$ and
                      K. Johnson and A. Keller and S. Smith and E. Sperk and R. P.
                      Symonds and F. Wenz and C. M. L. West and C. Herskind and C.
                      Bourgier},
      title        = {{M}ulti-centre technical evaluation of the
                      radiation-induced lymphocyte apoptosis assay as a predictive
                      test for radiotherapy toxicity.},
      journal      = {Clinical and translational radiation oncology},
      volume       = {18},
      issn         = {2405-6308},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2019-01901},
      pages        = {1 - 8},
      year         = {2019},
      abstract     = {Predicting which patients will develop adverse reactions to
                      radiotherapy is important for personalised treatment.
                      Prediction will require an algorithm or nomogram combining
                      clinical and biological data. The radiation-induced
                      lymphocyte apoptosis (RILA) assay is the leading candidate
                      as a biological predictor of radiotherapy toxicity. In this
                      study we tested the potential of the assay for
                      standardisation and use in multiple testing laboratories.
                      The assay was standardised and reproducibility determined
                      using samples from healthy volunteers assayed concurrently
                      in three laboratories in Leicester (UK), Mannheim (Germany)
                      and Montpellier (France). RILA assays were performed on
                      samples taken prior to radiotherapy from 1319 cancer
                      patients enrolled in the REQUITE project at multiple
                      centres. The patients were being treated for breast
                      (n = 753), prostate (n = 506) or lung (n = 60)
                      cancer. Inter-laboratory comparisons identified several
                      factors affecting results: storage time, incubation periods
                      and type of foetal calf serum. Following standardisation,
                      there was no significant difference in results between the
                      centres. Significant differences were seen in RILA scores
                      between cancer types (prostate > breast > lung), by
                      smoking status (non-smokers > smokers) and co-morbidity
                      with rheumatoid arthritis (arthritics > non-arthritics).
                      An analysis of acute radiotherapy toxicity showed as
                      expected that RILA assay does not predict most end-points,
                      but unexpectedly did predict acute breast pain. This result
                      may elucidate the mechanism by which the RILA assay predicts
                      late radiotherapy toxicity. The work shows clinical trials
                      involving multiple laboratory measurement of the RILA assay
                      are feasible and the need to account for tumour type and
                      other variables when applying to predictive models.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31341970},
      pmc          = {pmc:PMC6610684},
      doi          = {10.1016/j.ctro.2019.06.001},
      url          = {https://inrepo02.dkfz.de/record/144449},
}